An Extraordinary Milestone: €13.72 Million Secured to Advance Breast Cancer Diagnostics
The development and clinical validation of a diagnostic test for breast cancer patients represents a highly complex challenge- scientifically, technically, and, most importantly, financially. Ensuring patient safety, diagnostic accuracy, and clinical effectiveness is paramount, and achieving these standards requires substantial financial resources.
Until recently, the project was primarily financed through revenues from PCR testing during the pandemic. To progress to the next critical phase—clinical validation—additional funding was essential.
We are pleased to announce that we have successfully secured €8.12 million in investment from Crowdberry, Neulogy Ventures, Venture to Future Fund, and Lumus Investment. We extend our sincere gratitude to these investors for their confidence, support, and commitment to advancing the clinical validation of our Multiplex8+ diagnostic test.
In addition, under highly competitive conditions and rigorous expert review, we were awarded three Recovery Plan grants totaling €5.6 million. These grants will support not only clinical validation but also the further development of diagnostic solutions that leverage artificial intelligence, as well as the organization of an international oncology conference for experts across Central Europe and beyond.
Together, these funds amount to €13.72 million, representing a significant milestone in the advancement of breast cancer diagnostics. These resources will be strategically invested to make diagnostics faster, more accurate, and more reliable, ultimately helping to identify the most effective treatment options for patients confronting this severe disease.
This achievement reflects the extraordinary dedication, expertise, and commitment of the MultiplexDX International team, alongside visionary investors and innovative project management. It represents a significant step toward positioning Slovakia as a contributor to the global evolution of personalized medicine, with Multiplex8+poised to become available to patients who need it.
We extend our heartfelt thanks to all who have supported us—your trust and partnership make this progress possible.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
